ADITXT, INC. (ADTX)
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business